68Ga-DOTA-FAPI-04 PET/CT as a Promising Tool for Differentiating Ovarian Physiological Uptake: Preliminary Experience of Comparative Analysis With 18F-FDG

Wang, Qixin; Yang, Shun-Cheng; Tang, Wenxin; Liu, Lin; Chen, Yue

doi:10.3389/fmed.2021.748683

Cited by 7 publications

(6 citation statements)

References 28 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of these types of cancers could not be diagnosed accurately on 18 F-FDG PET/CT, because of the different glucose metabolic features of target cells. Besides, the 18 F-FDG uptake in ovarian is usually variable especially in patients at the reproductive ages because of physiological accumulation and affected by the menstrual cycle [ 17 ]. The results of this study revealed 68 Ga-FAPI PET/CT could demonstrate different types of ovarian malignancies including HGSC, LGSC, and mucinous carcinoma of the ovarian.…”

Section: Discussionmentioning

confidence: 99%

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Zheng

Liu

Feng

et al. 2022

Nuclear Medicine Communications

Self Cite

View full text Add to dashboard Cite

Background Currently, fluorine-18-fluorodeoxyglucose ( 18 F-FDG) is the most frequently used diagnostical radiotracer for PET/computed tomography (PET/CT) in ovarian malignancies. However, 18 F-FDG has some limitations. The fibroblast activation protein inhibitor (FAPI) previously demonstrated highly promising results in studies on various tumor entities and 68 Ga-labeled FAPI presents a promising alternative to 18 F-FDG. This study aimed to compare the performance of 68 Ga-FAPI and 18 F-FDG PET/CT for imaging of ovarian malignancies.Methods A total of 27 patients were included in this retrospective study conducted at the Affiliated Hospital of Southwest Medical University between June 2020 and February 2022. The 18 F-FDG and 68 Ga-FAPI uptakes of tumors, lymph nodes, and distant metastases were quantified using the maximum standardized uptake values, and the tumor-to-background ratios were also evaluated and calculated by using the Wilcoxon signedrank test. ResultsTwenty-one patients with suspected (n = 11) and previously treated ovarian malignancies (n = 10) were in statistical analysis finally. For detecting tumors, 68 Ga-FAPI PET/CT was more sensitive than 18 F-FDG PET/ CT [14 of 14 (100%) vs. 11 of 14 (78%)], lymph node metastases [75 of 75 (100%) vs. 60 of 75 (80%)] and superior to 18 F-FDG PET/CT in terms of the peritoneal and pleural metastases [9 of 9 (100%) vs. 5 of 9 (56%)]. For four of the newly diagnosed patients (n = 11), 68 Ga-FAPI PET/CT upstaged the clinical stage compared to 18 F-FDG PET/CT. Conclusion 68 Ga-FAPI PET/CT has superior potential in the detection of ovarian cancers, especially in peritoneal carcinomatosis. 68 Ga-FAPI PET/CT may be a promising supplement for staging and follow-up of ovarian malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Zheng

Liu

Feng

et al. 2022

Nuclear Medicine Communications

Self Cite

View full text Add to dashboard Cite

show abstract

“…A family of inhibitors of this protein based on a quinolone scaffold has been developed and labeled with several diagnostic and therapeutic radionuclides, such as 68 Ga ( 211 , 212 ). Among the FAPI derivatives developed, [ 68 Ga]Ga-FAPI-4 and [ 68 Ga]Ga-FAPI-46, with a DOTA chelator, led to impressive results ( 213 – 215 ). New derivatives suitable for cold kit radiolabeling were recently described, one with a NOTA chelator (FAPI-74) ( 216 ), and another with the DATA 5M chelator ( 217 ).…”

Section: Cold Kitsmentioning

confidence: 99%

Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Lepareur

2022

Front. Med.

View full text Add to dashboard Cite

Over the last couple of decades, gallium-68 (68Ga) has gained a formidable interest for PET molecular imaging of various conditions, from cancer to infection, through cardiac pathologies or neuropathies. It has gained routine use, with successful radiopharmaceuticals such as somatostatin analogs ([68Ga]Ga-DOTATOC and [68Ga]GaDOTATATE) for neuroendocrine tumors, and PSMA ligands for prostate cancer. It represents a major clinical impact, particularly in the context of theranostics, coupled with their 177Lu-labeled counterparts. Beside those, a bunch of new 68Ga-labeled molecules are in the preclinical and clinical pipelines, with some of them showing great promise for patient care. Increasing clinical demand and regulatory issues have led to the development of automated procedures for the production of 68Ga radiopharmaceuticals. However, the widespread use of these radiopharmaceuticals may rely on simple and efficient radiolabeling methods, undemanding in terms of equipment and infrastructure. To make them technically and economically accessible to the medical community and its patients, it appears mandatory to develop a procedure similar to the well-established kit-based 99mTc chemistry. Already available commercial kits for the production of 68Ga radiopharmaceuticals have demonstrated the feasibility of using such an approach, thus paving the way for more kit-based 68Ga radiopharmaceuticals to be developed. This article discusses the development of 68Ga cold kit radiopharmacy, including technical issues, and regulatory aspects.

show abstract

“…This finding was in contrast to the reported effects of [ 18 F]FDG, which exhibited accumulation in both malignant and functional ovarian lesions. This is a clear indicator of [ 68 Ga]Ga-FAPI as a differentiation radiotracer in gynecological malignancies [ 134 ].…”

Section: Recent Advances Of [ 68 Ga]ga-fapi In Var...mentioning

confidence: 99%

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies

Vahidfar

Farzanefar

Ahmadzadehfar

et al. 2022

Cancers

View full text Add to dashboard Cite

Nuclear medicine is defined as the diagnosis and the treatment of disease using radiolabeled compounds known as radiopharmaceuticals. Single-photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/computer tomography (PET/CT) based radiopharmaceuticals have proven reliable in diagnostic imaging in nuclear medicine and cancer treatment. One of the most critical cancers that also relies on an early diagnosis is gynecological cancer. Given that approximately 25% of all cancers in developing countries are a subset of gynecological cancer, investigating this cancer subtype is of significant clinical worth, particularly in light of its high rate of mortality. With accurate identification of high grade distant abdominal endometrial cancer as well as extra abdominal metastases, 18F-Fluorodeoxyglucose ([18F]FDG) PET/CT imaging is considered a valuable step forward in the investigation of gynecological cancer. Considering these factors, [18F]FDG PET/CT imaging can assist in making management of patient therapy more feasible. In this literature review, we will provide a short overview of the role of nuclear medicine in the diagnosis of obstetric and gynecological cancers.

show abstract

68Ga-DOTA-FAPI-04 PET/CT as a Promising Tool for Differentiating Ovarian Physiological Uptake: Preliminary Experience of Comparative Analysis With 18F-FDG

Cited by 7 publications

References 28 publications

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies

Contact Info

Product

Resources

About